Skip to main content
Equibles
ICCC logo

ICCC · Immucell Corp · Metrics

Track ICCC — free

Use ICCC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ICCC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.80 -0.15 (-1.51%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$90.37M
Shares
9.08M
Volume · Nov 6 8244 Avg daily vol (3M) 16.72K

ICCC metrics

103 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.80
Market cap
$90.37M

Price action

23 metrics
Price change (1W)
-3.6%
Price change (30D)
+2.7%
Price change (3M)
-9.7%
Price change (6M)
+17.5%
Price change (YTD)
+61.8%
Price change (1Y)
+57.9%
Trailing year
Price change (5Y)
+10.7%
52-week high
$11.72
52-week low
$4.56
Change from 52-week high
-15.1%
Change from 52-week low
+118.2%
Annualized volatility
50.7%
Annualized volatility (3M)
39.0%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.4
RSI (14D)
44.2
Price vs SMA 50
-1.2%
Price vs SMA 200
+11.3%
Avg volume (3M)
17,233
Relative volume
0.4
Average dollar volume
$174,308

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.08M

Valuation

12 metrics
P / E (TTM)
142.1
Trailing earnings · reciprocal yield 0.7%
PEG ratio
0.6
EV / revenue
2.9×
reciprocal yield 34.2%
EV / EBITDA
14.3×
reciprocal yield 7.0%
EV / EBIT
23.2×
reciprocal yield 4.3%
P / sales
2.9×
reciprocal yield 33.9%
P / book
2.9
reciprocal yield 34.7%
FCF yield
4.7%
TTM · current market cap
Buyback yield
—
P / FCF
21.4
reciprocal yield 4.7%
P / operating cash flow
15.3
reciprocal yield 6.5%
Earnings yield
0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
355.8×
reciprocal yield 0.3%
EV / revenue historical average (3Y)
2.6×
reciprocal yield 39.0%
EV / revenue historical average (5Y)
2.7×
reciprocal yield 36.9%
EV / EBIT historical average (3Y)
30.1×
reciprocal yield 3.3%
EV / EBIT historical average (5Y)
74.3×
reciprocal yield 1.3%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-13
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
40.3%
Operating margin
12.6%
Trailing 12 months
Net margin
2.6%
Gross profit (TTM)
$12.37M
Operating profit (TTM)
$3.87M
Net income (TTM)
$787,373
Trailing 12 months
Diluted EPS (TTM)
$0.07
FCF margin
13.7%
Effective tax rate
7.8%

Per share

11 metrics
Revenue per diluted share (TTM)
$3.38
Gross profit per diluted share (TTM)
$1.36
Operating profit per diluted share (TTM)
$0.42
EBITDA per diluted share (TTM)
$0.69
Net income per diluted share (TTM)
$0.08
Operating cash flow per diluted share (TTM)
$0.65
Free cash flow per diluted share (TTM)
$0.46
Capital expenditures per diluted share (TTM)
$0.18
R&D per diluted share (TTM)
$0.21
Stock compensation per diluted share (TTM)
$0.06
Book value per share
$2.99

Growth

11 metrics
Revenue growth YoY
+11.5%
Year over year
Net income growth YoY
+265.6%
Revenue (TTM)
$30.68M
Trailing 12 months
EPS growth YoY
+233.3%
Shares change YoY
+1.7%
Year over year · more shares
Revenue CAGR (3Y)
+14.2%
Revenue CAGR (5Y)
+12.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
2.5%
Return on assets
1.7%
Debt / equity
0.3
Current ratio
4.8
EBITDA (TTM)
$6.29M
Free cash flow (TTM)
$4.21M
Quick ratio
2.7
Interest coverage
8.9
Net debt / EBITDA
-0.1
Return on invested capital
11.6%
Trailing 12 months
Net cash
$557,319
Latest balance sheet
Cash & equivalents
$8.86M
Total assets
$46.63M
Total debt
$8.30M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$5.89M
Capital expenditures (TTM)
$1.68M
R&D (TTM)
$1.89M
SG&A (TTM)
—
Stock compensation (TTM)
$554,758
R&D / revenue
6.2%
Stock compensation / revenue
1.8%

Ownership (13F)

9 metrics
13F filers
32
13F filer change QoQ
+4
Institutional ownership
15.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
6.3%
Private-fund adviser ownership
6.0%
Active holders' share change QoQ
-4.7%
Holder tenure
15.7
Price vs estimated holder cost
+40.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.8%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 811641 CUSIP 452525306 13F (30d) 16 filings 9 filers Visit website Investor relations